Search research articles
Contact Us
Filters
Showing results (141-150 of 161) with videos related to
Page
of 17
Sort By:
The Journal of Infectious Diseases
|
September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways
Samuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 15, 2024
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy
Simon J Hume, Danny K Wong, Man-Fung Yuen, et al.
Springerplus
|
September 3, 2016
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3
Graham R Foster, Kazuaki Chayama, Wan-Long Chuang, et al.
Hepatology Communications
|
July 17, 2023
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants
Alexander J Thompson, Kathy Jackson, Sara Bonanzinga, et al.
Gastroenterology
|
October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
Patrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
The Lancet. Gastroenterology & Hepatology
|
May 22, 2026
The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729-001): a phase 1a/b trial
Man-Fung Yuen, Edward Gane, Jacinta A Holmes, et al.
Hepatology International
|
January 25, 2022
Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
George Lau, Ming-Lung Yu, Grace Wong, et al.
Hepatology International
|
August 24, 2021
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
George Lau, Ming-Lung Yu, Grace Wong, et al.
Cancers
|
December 23, 2023
Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort Study
Jonathan Abdelmalak, Simone I Strasser, Natalie Ngu, et al.
The New England Journal of Medicine
|
August 18, 2016
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Frederik Nevens, Pietro Andreone, Giuseppe Mazzella, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 161) with videos related to
Sort By:
Page
of 17
The Journal of Infectious Diseases
|
September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways
Samuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 15, 2024
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy
Simon J Hume, Danny K Wong, Man-Fung Yuen, et al.
Springerplus
|
September 3, 2016
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3
Graham R Foster, Kazuaki Chayama, Wan-Long Chuang, et al.
Hepatology Communications
|
July 17, 2023
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants
Alexander J Thompson, Kathy Jackson, Sara Bonanzinga, et al.
Gastroenterology
|
October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
Patrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
The Lancet. Gastroenterology & Hepatology
|
May 22, 2026
The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729-001): a phase 1a/b trial
Man-Fung Yuen, Edward Gane, Jacinta A Holmes, et al.
Hepatology International
|
January 25, 2022
Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
George Lau, Ming-Lung Yu, Grace Wong, et al.
Hepatology International
|
August 24, 2021
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
George Lau, Ming-Lung Yu, Grace Wong, et al.
Cancers
|
December 23, 2023
Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort Study
Jonathan Abdelmalak, Simone I Strasser, Natalie Ngu, et al.
The New England Journal of Medicine
|
August 18, 2016
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Frederik Nevens, Pietro Andreone, Giuseppe Mazzella, et al.
Page
of 17